PIK3CA and tumor of adipose tissue: Recently, patients with lipomatous tumors associated with a related spectrum of syndromes caused by mosaic activating PI3K mutations (PIK3CA-related overgrowth syndrome, PROS) were successfully treated with the novel PI3K inhibitor alpelisib (BYL-719) [8].